Skip to main content

Overview

My medical and scientific career began with, and continues to involve, investigations concerning the biology of the human lung, with a focus over the past decade on health and disease of the airway epithelium and lower respiratory tract. Over 40 years ago, I collaborated with Herb Reynolds and utilized bronchoalveolar lavage to study inflammation on the epithelial surface of the lower respiratory tract.

This research opened the door to a major series of studies that helped to define the pathogenesis and therapy of fibrotic lung diseases. Following that breakthrough, our laboratory helped to define the pathogenesis of Alpha-1 Antitrypsin (AAT) deficiency and - most crucially - developed AAT augmentation therapy, the FDA-approved therapy that has been used since 1988 to treat thousands of AAT deficiency patients worldwide.

Highlights

  1. 1
    American journal of respiratory and critical care medicine · 2020
    PMID: 32432483PMCID: PMC7365377DOISenior author197 citations
  2. 2
    Science translational medicine · 2020
    PMID: 33268510PMCID: PMC8056991DOISenior author72 citations
  3. 3
    Human gene therapy · 2020
    PMID: 33233962PMCID: PMC7769048DOISenior author36 citations

Publications

937 publications

Active

21 grants
  • PI
    MSA between Genetic Cures for Kids Inc and Weill Cornell Medicine
    Genetic Cures for Kids Inc · 2024–2030Contract
    SA 234382-01
  • MPI
    MSA with University of Sheffield and Weill Cornell
    University of Sheffield · 2019–2030Contract
    SA 202209-02
  • PI
    MSA between Weill Cornell and Bionic Sight
    Bionic Sight · 2022–2030Contract
    SA 226146-03
  • PI
    Gene Therapy for Alpha 1-Antitrypsin Deficiency
    National Heart, Lung, and Blood Institute · 2024–2028
    R33HL169190-03
  • PI
    Gene Therapy for APOE4 Homozygous Alzheimer's Disease
    National Institute on Aging · 2026–2028
    UG3AG098024-01
  • KP
    Treatment of APOE4-associated Cognitive Decline in Parkinson's Disease by an Adeno-associated Virus Coding for the Combined APOE2 and APOE-Christchurch Variant
    Michael J. Fox Foundation for Parkinson's Research · 2025–2027
    MJFF 251995-01
  • PI
    Prime Editing of CNS APOE4 to APOE2 or APOE3Christchurch to Suppress Alzheimer's Disease APOE4-associated Amyloid and Tau Pathology
    National Institute on Aging · 2026–2027
    R56AG095450-01A1
  • PI
    Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia
    National Heart, Lung, and Blood Institute · 2020–2027
    R33HL151355-04
  • PI
    Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency in Post-menopausal East Asian Women
    NIAAA · 2020–2027 · via NIH RePORTER
    R42AA028465-03
  • PI
    MSA between Forge Biologics and Weill Cornell
    Forge Biologics · 2022–2027Contract
    SA 225750-01
  • PI
    Amendment MSA between WCMC and Bionic
    Bionic Sight · 2026–2027Contract
    SA 262133-01
  • MPI
    Ancillary SOURCE Study: Characterization of Small Airway Basal Cell Biology in Early COPD
    National Heart, Lung, and Blood Institute · 2023–2027
    R01HL166983-04
  • PI
    MSA between UMASS and Weill Cornell University
    University of Massachusetts · 2022–2027Contract
    SA 223745-01
  • Co-I
    Distinct and Overlapping Pathways of Fibrosis and Emphysema in Cigarette Smokers
    National Heart, Lung, and Blood Institute · 2021–2027
    P01HL114501-06A1
  • PI
    MSA between ENYX Therapeutics LLC and Weill Cornell
    ENYX Therapeutics, LLC · 2022–2027Contract
    SA 224519-01
  • PI
    Lexeo Biopharma Agreement
    LEXEO Therapeutics, Inc. · 2025–2027BioPharma Alliance
    BP 251293-03
  • KP
    Tranexamic Acid: Is It As Safe As We Think?
    American Society for Aesthetic Plastic Surgery · 2024–2026
    No publications yet
    ASAPS 245963-01
  • MPI
    MSA between Weill Cornell and FormBio
    Form Bio INC · 2025–2026Contract
    SA 251940-01
  • KP
    New PET/CT System for Human and Non-human Primate Imaging
    Office of the Director, NIH · 2023–2026
    S10OD034271-01
  • PI
    Gene Therapy-mediated Angiogenesis to Enhance Survival of Transplanted Fat
    NHLBI · 2024–2026 · via NIH RePORTER
    R41HL170928-01A1
  • PI
    Safety of AAV-mediated C1 Esterase Inhibitor Gene Therapy for Hereditary Angioedema
    NIAID · 2024–2025 · via NIH RePORTER
    R41AI181097-01
Completed grants (78)
  • Sub-PI
    Increased Dorsal Skin Flap Survival with Ad5VEGF(3i)
    NYSTAR · 2024–2025 · via Cornell University - Ithaca
    CU 243667-01
  • MPI
    Rapid Noninvasive Whole-body Imaging of AAV Gene Transfer Vectors
    National Institute of Biomedical Imaging and Bioengineering · 2019–2025
    R01EB027918-03
  • PI
    MSA between Weill Cornell and LEXEO Therapeutics LLC
    LEXEO Therapeutics, Inc. · 2021–2025Contract
    SA 212795-01
  • PI
    MSA between Weill Cornell and LEXEO Therapeutics LLC
    LEXEO Therapeutics, Inc. · 2021–2025Contract
    SA 212795-01
  • PI
    Manufacturing Services Agreement between PTC and WCM
    PTC Therapeutics · 2019–2024Contract
    SA 201427-01
  • PI
    Angiogenesis Gene Therapy to Enhance Survival of Transplanted Fat
    Daedalus Fund for Innovation (Weill Cornell) · 2023–2024BioPharma Alliance
    BP 233474-01
  • Co-I
    Understanding the Origins of Early COPD
    National Heart, Lung, and Blood Institute · 2020–2024
    R01HL144718-01A1
  • PI
    Anti-eosinophil Gene Therapy for Eosinophilic Esophagitis
    NIAID · 2022–2024 · via NIH RePORTER
    R41AI165000-01A1
  • MPI
    MSA with University of Pittsburgh and Cornell
    University of Pittsburgh · 2020–2024Contract
    SA 204534-01
  • PI
    Lexeo Biopharma Agreement
    LEXEO Therapeutics, Inc. · 2022–2024BioPharma Alliance
    BP 213795-02
  • PI
    Clinical Assessment of Anti-cocaine Vaccine dAdGNE in Cocaine Addicts
    National Institute on Drug Abuse · 2019–2024
    U01DA048524-02
  • PI
    Xylocor Master Services Agreement for AdVEGF-All6A+
    XyloCor · 2019–2023Contract
    SA 191897-01
  • Sub-PI
    Precision Pharmacogenomics in Qatar
    Qatar National Research Fund · 2020–2023 · via Weill Cornell Medical College/Qatar
    PPM3-0314-190024
  • KP
    Major Cyclotron Upgrades and Refurbishment
    Office of the Director, NIH · 2021–2023
    S10OD030447-01
  • KP
    AAV-Based Gene Therapy for the Long-Term Treatment of CLN2-Associated Retinal Degeneration and Prevention of Blindness in CLN2 Patients
    Daedalus Fund for Innovation (Weill Cornell) · 2021–2023BioPharma Alliance
    BP 214968-01
  • PI
    Phase I Study of an AAVrh.10-Mediated Apolipoprotein E2 Gene Delivery to the CNS for the Treatment of Alzheimer's Disease in E4 Homozygotes
    Alzheimer's Drug Discovery Foundation · 2018–2023
    ADDF 171089-03
  • PI
    MSA Amendment No.2 between Lexeo Therapeutics and Weill Cornell
    LEXEO Therapeutics, Inc. · 2022–2022Contract
    LEXEO-01
  • KP
    Second Generation Gene Therapy for APOE4 Homozygous Individuals at High Risk for Alzheimer's Disease
    National Institute on Aging · 2021–2022
    R03AG070738-01
  • KP
    Comparison of Brain Biodistribution of Two CDKL5 Gene Therapy Vector Leads
    Orphan Disease Center at University of Pennsylvania · 2021–2022
    No publications yet
    ODCUP 214052-01
  • Co-I
    Precision Pharmacogenomics in Qatar
    Qatar National Research Fund · 2020–2022
    PPM 03-0314-190024
  • PI
    Oxidation-resistant Anti-protease Therapy
    NHLBI · 2018–2022 · via NIH RePORTER
    R42HL140670-03
  • PI
    CNS Gene Therapy for CLN2 Disease Using Parallel Multiple Routes of Administration
    NINDS · 2020–2022 · via NIH RePORTER
    R41NS117265-01
  • PI
    Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency
    NIAAA · 2020–2022 · via NIH RePORTER
    R41AA028465-01
  • PI
    Lexeo Biopharma Agreement
    LEXEO Therapeutics, Inc. · 2021–2022BioPharma Alliance
    BP 213795-01
  • PI
    Vaccine to Treat Fentanyl Addiction and Overdose"
    Cornell University · 2021–2021
    CUI 211771-01
  • Co-I
    Metabolic Dysfunction Regulates Mitophagy-Dependent Necroptosis in COPD
    National Heart, Lung, and Blood Institute · 2017–2021
    R01HL132198-02
  • MPI
    Corneal Confocal Microscopy Quantitative Imaging of Corneal Nerves as a Biomarker of Neurologic Disease in Friedreich's Ataxia
    Friedreich's Ataxia Research Alliance · 2019–2021
    FARA 194201-01
  • PI
    Gene Therapy for Cardiac Manifestations of Friedreich's Ataxia
    Friedreich's Ataxia Research Alliance · 2019–2021
    FARA 194278-01
  • PI
    In Vivo Biomarker that Identifies Waterpipe Smoking-Related Lung Health
    National Heart, Lung, and Blood Institute · 2016–2021
    R01HL134163-03
  • PI
    Gene Therapy for Chronic Traumatic Encephalopathy
    Daedalus Fund for Innovation (Weill Cornell) · 2019–2021BioPharma Alliance
    DFI 200106-01
  • PI
    Pulmonary Genetic Medicine Training Program
    National Heart, Lung, and Blood Institute · 2015–2021Training
    T32HL094284-10
  • PI
    Integrative-omics Network Model of the Disordered COPD Small Airway Epithelium
    National Heart, Lung, and Blood Institute · 2014–2021
    R01HL118541-04
  • PI
    HIV Reprogrammed Airway Basal Cells Acquire a “Tissue Destructive” Phenotype
    National Heart, Lung, and Blood Institute · 2016–2021
    R01HL134549-04
  • PI
    Vector Production - Oxidation-resistant Anti-protease Therapy
    LEXEO Therapeutics, Inc. · 2018–2021Contract
    SRA 182697-03
  • PI
    Gene Therapy to Protect the Lung from Oxidant Stress
    NHLBI · 2019–2020 · via NIH RePORTER
    R41HL145871-01A1
  • PI
    Assessment and Gene Repair of Human CF Airway Basal Stem/Progenitor Cells
    Cystic Fibrosis Foundation · 2016–2020
    CRYSTAL15XX0EWOF
  • KP
    Design and Implementation of the First Qatari Population-Centric High-Throughput Custom-Genotyping Microarray, With an Accompanying Private Qatari Genome Browser
    Qatar National Research Fund · 2016–2020 · via Weill Cornell Medical College/Qatar
    NPRP8-1913-3-396
  • PI
    MOU for Martina Bradic
    Weill Cornell Medical College/Qatar · 2019–2020Contract
    SA 194768-01
  • PI
    Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency
    NIAAA · 2019–2020 · via NIH RePORTER
    R41AA027739-01
  • PI
    Schedule D
    Annapurna Therapeutics · 2015–2019Contract
    AT SA
  • PI
    BI- IPF Therapy
    Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · 2017–2019Contract
    BP 182046-01
  • PI
    MOU for Martina Bradic
    Weill Cornell Medical College/Qatar · 2018–2019Contract
    SA 190892-01
  • PI
    Amendment 1 to Crystal Boehringer Ingleheim Service Agreement
    Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · 2018–2019Contract
    SA 190353-01
  • PI
    HIV+ Alveolar Macrophage Oxidant-Mediated Apoptosis of Pulmonary Endothelium
    National Heart, Lung, and Blood Institute · 2013–2019
    U01HL121828-05
  • Sub-PI
    Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis
    Qatar National Research Fund · 2013–2019 · via Hamad Medical Corporation
    NPRP 6-1348-3-321
  • Co-I
    Parametric Response Mapping in COPD
    National Heart, Lung, and Blood Institute · 2017–2019 · via The Regents of the University of Michigan
    R01HL122438-04S1
  • PI
    Biology of the Oral Epithelium of E-Cigarette Smokers
    National Institute of Dental and Craniofacial Research · 2016–2019
    R56DE026027-03
  • PI
    HIV-Related Accelerated Aging of the Airway Epithelium
    National Heart, Lung, and Blood Institute · 2013–2019
    R01HL118857-05
  • PI
    Production of GMP grade adeno-associated viral vector serotype 5 vector-UPENN-Beltran
    University of Pennsylvania · 2018–2019Contract
    SA 183632-01
  • PI
    A Human Embryonic Stem Cell-based Platform for Directed Evolution of Viral Tropism to Generate Cell-type Specific Vectors for Gene Therapy
    Daedalus Fund for Innovation (Weill Cornell) · 2017–2018
    DFI 180062-01
  • KP
    Identification and Characterization of Bone-Related Genetic Variants in Families
    Qatar National Research Fund · 2015–2018 · via Hamad Medical Corporation
    NPRP 7-1301-3-336
  • KP
    Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy: A Gene Therapy Approach
    Parker B. Francis Foundation · 2015–2018Fellowship
    PBF 170604-01
  • PI
    Disrupted Adenovirus Serotype 5-Based Anti-Cocaine Vaccine
    National Institute on Drug Abuse · 2012–2018
    U01DA033835-03
  • PI
    COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function
    NHLBI · 2012–2018 · via NIH RePORTER
    P20HL113443-05
  • PI
    Pulmonary Genetic Medicine Training Program-Administrative Supplement
    National Heart, Lung, and Blood Institute · 2016–2017Training
    No publications yet
    R03HL140406-01
  • PI
    Second-Generation Gene Transfer Vector-Based Anti-Cocaine Vaccines
    National Institute on Drug Abuse · 2013–2017
    R01DA032702-03
  • PI
    Management Project - Gene Therapy for Metachromatic Leukodystrophy
    NINDS · 2011–2016 · via NIH RePORTER
    U01NS066920-03
  • KP
    Subpopulation and Intermediate Outcome Measure in COPD Study SPIROMICS: Clinical Center
    National Heart, Lung, and Blood Institute · 2009–2016
    HHSN268200900017C EW
  • PI
    Gene Therapy for Batten Disease Using AAVrh.10 Expressing Human CLN2 cDNA
    National Institute of Neurological Disorders and Stroke · 2010–2016
    R01NS061848-04EWO
  • PI
    Overlapping Airway Basal Cell Transcriptome Reprogramming in COPD and Lung Cancer
    National Heart, Lung, and Blood Institute · 2011–2016
    R01HL107882-04 EW
  • MPI
    Genetically-delivered Bevacizumab for Treatment of Wet Age-Related Macular Degene
    NEI · 2013–2015 · via NIH RePORTER
    R43EY023108-01
  • KP
    LDN: Assessment of Neurological Deterioration in Subjects with LINCL
    National Institute of Neurological Disorders and Stroke · 2009–2014 · via University of Minnesota
    U54NS065768-03
  • MPI
    Adenovirus-Based Nanoparticle Vaccines
    National Institute on Drug Abuse · 2009–2014
    R01DA025305-03
  • MPI
    Administration
    NHLBI · 2006–2011 · via NIH RePORTER
    P50HL084936-05
  • PI
    Adenovirus-Based Anti-Cocaine Vaccine
    National Institute on Drug Abuse · 2009–2011
    RC2DA028847-02 EW
  • PI
    Gene Therapy for Batten Disease
    NINDS · 2005–2010 · via NIH RePORTER
    U01NS047458-05
  • PI
    Gene Therapy for Cystic Fibrosis
    NHLBI · 1993–2009 · via NIH RePORTER
    P01HL051746-15
  • MPI
    Vaccine Platforms
    NIAID · 2008–2009 · via NIH RePORTER
    U54AI057158-05S1
  • MPI
    Weill Cornell Program of Excellence in Gene Therapy
    NHLBI · 2000–2008 · via NIH RePORTER
    U01HL066952-06
  • PI
    Candidate Genes for Susceptibility to Bronchitis
    NHLBI · 2004–2008 · via NIH RePORTER
    R01HL074326-04
  • MPI
    Anti-Y. pestis Vaccination and Passive Protection
    NIAID · 2003–2007 · via NIH RePORTER
    R01AI055844-01
  • MPI
    GENE TRANSFER VECTOR HUMAN CLN2 CDNA BRAIN OF CHILDREN LINCL
    NCRR · 1997–2007 · via NIH RePORTER
    M01RR000047-47
  • MPI
    Manipulation of VEGF splicing in angiogenic gene therapy
    NHLBI · 1997–2007 · via NIH RePORTER
    P01HL059312-10
  • PI
    PEGT Coordinating and Data Core at Weill Cornell
    NHLBI · 2000–2005 · via NIH RePORTER
    U01HL067738-01S1
  • MPI
    SHH INDUCTION OF POST-NATAL HAIR FOLLICLE/HAIR GROWTH
    NIAMS · 2000–2005 · via NIH RePORTER
    R01AR046282-03
  • MPI
    REGIONAL INDUCTION OF ANGIOGENESIS BY IN VIVO GENE TRANSFER
    NHLBI · 1997–2003 · via NIH RePORTER
    P50HL056987-05
  • MPI
    GENE TRANSFER TO ALVEOLAR MACROPHAGES
    NHLBI · 1997–2002 · via NIH RePORTER
    P50HL059312-05
  • PI
    REGIONAL ANGIOGENESIS INDUCED BY IN VIVO GENE THERAPY
    NHLBI · 1998–2002 · via NIH RePORTER
    R01HL057318-04

Honors & distinctions

4 honors
  • Joan and Sanford I. Weill Exemplary Achievement Award · Weill Cornell Medicine · 2026
  • Fellow · National Academy of Inventors · 2021
  • Member · American Society for Clinical Investigation · 1978
  • Member · Association of American Physicians

Clinical research

3 studies

Active

3 studies
  • PI
    Gene Therapy for Alpha 1- Antitrypsin Deficiency
    PHASE1 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
    Alpha 1-Antitrypsin Deficiency
    NCT06996756
  • PI
    Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
    PHASE1 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2022)
    Friedreich Ataxia; Cardiomyopathies; Cardiac Hypertrophy; Myocardial Fibrosis
    NCT05302271
  • PI
    Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2019)
    Friedreich's Ataxia
    NCT02316314

Available technologies

Show 7 more technologies

News mentions

  • Gene Therapy Pioneer Dr. Ronald G. Crystal Honored with Weill Award
    November 13, 2026

    Dr. Ronald G. Crystal, chair of the Department of Genetic Medicine and the Bruce Webster Professor of Internal Medicine at Weill Cornell Medicine, has been awarded the institution’s Joan and Sanford I. Weill Exemplary Achievement Award.

  • Weill Cornell Medicine Awarded Grant for Alzheimer’s Gene Therapy Research
    July 8, 2026

    The National Institute on Aging of the National Institutes of Health has awarded a five-year grant initially worth $8.37 million for Weill Cornell Medicine researchers to study a new gene therapy for Alzheimer’s disease in people who have a high genetic risk of developing the condition. The research could garner nearly $14 million in total if prescribed milestones are reached for years three through five.

  • Gene Therapy Shows Promise for Life-Threatening Inherited Heart Disease
    June 17, 2026

    A new gene therapy appears to be safe in patients diagnosed with Friedreich ataxia cardiomyopathy, a progressive and fatal inherited cardiac disease, according to a phase 1 clinical trial led by Weill Cornell Medicine researchers.

  • Dr. Ronald Crystal Elected Fellow of National Academy of Inventors
    December 20, 2021

    Dr. Ronald Crystal, chairman of the Department of Genetic Medicine and the Bruce Webster Professor of Internal Medicine at Weill Cornell Medicine, has been elected a fellow of the National Academy of Inventors

  • Gene Therapy Shows Promise in Batten Disease
    December 9, 2020

    A gene therapy developed by Weill Cornell Medicine and NewYork-Presbyterian investigators helped slow progression of a rare and fatal genetic disorder in children called late infantile Batten disease, in a phase 1 clinical study.

Show 1 more mention
1 MD student · 1 PhD student · 19 Postdocs

External relationships

Leadership Roles

ENYX Therapeutics LLC

Ownership

Adverum Biotechnologies · ENYX Therapeutics LLC · Jannu Therapeutics · LEXEO Therapeutics, Inc. · REGENX Bio, Inc. · XyloCor Therapeutics

Professional Services

Passage Bio, Inc.

Proprietary Interest

Center for Technology Licensing at Cornell University · LEXEO Therapeutics, Inc. · XyloCor Therapeutics

Other

4D Molecular Therapeutics, Inc. · AlphaSights, Inc · Atheneum Partners · ClearView Healthcare Partners · Coleman Research Group · EcoR1 Capital LLC · Gerson Lehrman Group (GLG) · GlaxoSmithKline · Guidepoint Global LLC · LEXEO Therapeutics, Inc. · MEDACorp · XyloCor Therapeutics